Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3M | $125M | $224M | $339M | $442M | $484M | $517M | $726M | $958M | $1.07B |
| Revenue growth | — | 620.7% | 79.2% | 51.5% | 30.3% | 9.6% | 6.8% | 40.4% | 31.8% | 11.9% |
| Gross profit | $14.3M | $116M | $211M | $328M | $432M | $473M | $507M | $685M | — | — |
| Gross margin | 82.2% | 92.7% | 94.5% | 96.7% | 97.7% | 97.8% | 98.0% | 94.3% | — | — |
| Operating income | -$273M | -$292M | -$247M | -$247M | -$287M | -$170M | -$224M | -$73.4M | $231M | $105M |
| Operating margin | -1574.1% | -234.1% | -110.6% | -72.7% | -64.9% | -35.2% | -43.2% | -10.1% | 24.1% | 9.8% |
| Net income | -$271M | -$289M | -$245M | -$235M | -$282M | -$168M | -$216M | -$61.3M | $226M | $391M |
| Net margin | -1565.9% | -231.7% | -109.6% | -69.4% | -63.7% | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% |
| EPS (diluted) | -$2.34 | -$2.36 | -$1.94 | -$1.60 | -$1.79 | -$1.05 | -$1.34 | -$0.37 | $1.36 | $2.30 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$208M | -$218M | -$167M | -$151M | -$136M | -$126M | -$114M | $16.7M | $158M | $110M |
| Capital expenditures | $1.51M | $812K | $2.10M | $1.13M | $7.59M | $1.12M | $0.00 | $50.0K | $523K | $4.69M |
| Free cash flow | -$210M | -$219M | -$170M | -$152M | -$144M | -$127M | -$114M | $16.7M | $157M | $105M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $164M | $69.4M | $135M | $190M | $326M | $147M | $115M | $189M | $320M | $178M |
| Total assets | $561M | $385M | $540M | $783M | $783M | $700M | $588M | $749M | $1.19B | $1.56B |
| Total liabilities | $42.7M | $49.2M | $61.1M | $84.0M | $156M | $159M | $187M | $317M | $455M | $337M |
| Shareholders' equity | $518M | $335M | $479M | $699M | $627M | $541M | $400M | $432M | $733M | $1.23B |
| Retained earnings | -$934M | -$1.22B | -$1.47B | -$1.70B | -$1.99B | -$2.15B | -$2.37B | -$2.43B | -$2.20B | -$1.81B |
| Shares (wtd avg diluted) | 121M | 124M | 144M | 155M | 157K | 160K | 162M | 164M | 166M | 170M |
Every figure is extracted from ACADIA PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.